Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesTreatment Resistant Hypertension
American Journal of Therapeutics, 07/23/08
Bolli P et al. - White coat hypertension as a cause of treatment resistance is suspected if there is no target organ damage or if the patients complain of symptoms of hypotension during antihypertensive treatment. Secondary forms of hypertension, although comprising only approximately 5% of patients with treatment resistant hypertension, are important to identify because they may represent a curable form of hypertension.
| Previous Article | Next Article |
Today in Vascular Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet - Early Online Publication, 06/09/09
Management of hypertension in acute stroke
Expert Review of Cardiovascular Therapy , 06/12/09
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials
Vascular Health and Risk Management, 05/11/09
Sponsor
Article Search
Sponsor